ArticleBriefings in bioinformatics2025
Pushing the boundaries of few-shot learning for low-data drug discovery with a Bayesian meta-learning hypernetwork framework.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in drug discovery from advanced molecular representation to pipeline applications.Frontiers in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hunting for candidate compounds with favorable pharmacological, toxicological, and pharmacokinetic properties in drug discovery is essentially a low-data problem, as data acquisition is both challenging and costly. This inherent data limitation clashes with the requirements of many powerful deep learning models, which typically require large datasets. Here, we present Meta-Mol, a novel few-shot learning framework based on Bayesian Model-Agnostic Meta-Learning. Meta-Mol introduces a novel atom-bond graph isomorphism encoder that captures molecular structure information at the atomic and bond levels. This representation is further enhanced by a Bayesian meta-learning strategy, allowing for task-specific parameter adaptation and reducing overfitting risks. Additionally, a hypernetwork is employed to dynamically adjust weight updates across tasks, facilitating more complex posterior estimation. Our results demonstrate that Meta-Mol significantly outperforms existing models on several benchmarks, providing a robust solution to address data scarcity in drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.